Walgreens Boots Alliance stock falls as investors watch leverage and earnings

Walgreens Boots Alliance (US9314271019) remains a closely watched name after its latest reported quarter showed a net loss of $3.0 billion for the three months ended 31 May 2026, while adjusted earnings per share were $0.63 and sales were $37.5 billion. The company also carried long-term debt of $7.4 billion at quarter-end, a balance that keeps the financing story as important as the operating one.

Losses and leverage

The quarterly numbers matter because they frame the stock around cash flow and balance-sheet repair rather than simple top-line growth. In the same period, adjusted EBIT was $1.2 billion, and gross margin was 18.4%, both figures that show the business still generates scale even as reported profit stayed deep in the red.

For investors, the comparison is the key point: sales of $37.5 billion in the quarter were accompanied by a $3.0 billion net loss, a gap that underlines how much accounting charges and restructuring still shape the headline result. The latest report also showed free cash flow of $1.1 billion over the trailing twelve months, which adds an important liquidity reference point.

Quarterly comparison matters

Walgreens Boots Alliance said adjusted EPS of $0.63 for the quarter, and that sits against the prior-year period when the company was still working through a different earnings base. The market tends to focus less on the single-quarter figure than on whether margins, debt and cash generation can keep moving in the right direction through fiscal 2026.

The current setup is also more than a one-line earnings story. The company reported 8,500 retail locations at quarter-end, and that store base still anchors the operating model even as management continues to reshape the portfolio.

Boots remains central

Boots is still one of the most important businesses inside Walgreens Boots Alliance, with the chain contributing to group-scale revenue and pharmacy traffic across the United Kingdom and Ireland. In the latest reporting period, the international segment helped support the overall $37.5 billion sales figure, while management kept attention on cost control and working capital.

The product angle is less about one branded item than about the retail pharmacy mix itself. Prescription volumes, front-end traffic and private-label sales all feed the same earnings line, which is why the market keeps reading the segment data alongside the group numbers.

Shares and market value

The stock is best judged against valuation and balance-sheet repair, not against a single day of price noise. With the company still reporting a multibillion-dollar quarterly loss and $7.4 billion of long-term debt, the equity story remains tied to execution across the next several quarters.

Walgreens Boots Alliance stock last traded with a market capitalization of about $7.0 billion, a scale that reflects the market's caution toward the turnaround and the debt load. That valuation sits alongside the latest quarterly sales of $37.5 billion and adjusted EPS of $0.63, which is the mix investors are still trying to reconcile.